Previously, mice whose anti-oxLDL IgM antibody levels were increased by means of heat-inactivated S. pneumoniae displayed reduced disease burden in the context of NASH, NPC1 disease and atherosclerosis, strengthening the hypothesis that increasing anti-oxLDL antibody levels may be beneficial in humans. This evidence concerns the gene CD40LG and metabolic dysfunction-associated steatohepatitis.